Does Medicare Cover Entyvio for Crohn's Disease and Ulcerative Colitis?

Introduction: Understanding Entyvio and Its Role in IBD Treatment

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, affects millions worldwide. These chronic conditions cause inflammation in the digestive tract, leading to debilitating symptoms like abdominal pain, severe diarrhea, fatigue, and weight loss. For many individuals living with IBD, managing symptoms and achieving remission requires advanced therapies, including biologic medications.

One such biologic is Entyvio (vedolizumab), an intravenous medication specifically designed to treat moderate to severe active Crohn's disease and ulcerative colitis. Entyvio works by selectively targeting and blocking inflammatory cells from entering the gut lining, thereby reducing inflammation and helping patients achieve sustained remission. Given its effectiveness, Entyvio is a crucial treatment option for many, but its high cost often raises concerns about insurance coverage, particularly for Medicare beneficiaries.

This comprehensive guide will delve into how Medicare covers Entyvio, breaking down the different parts of Medicare and exploring potential out-of-pocket costs, eligibility criteria, and financial assistance programs. Understanding your coverage options is vital to ensuring uninterrupted access to this life-changing medication.

What is Entyvio (Vedolizumab)?

Entyvio is a prescription medication used to treat adults with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD) when other treatments have not worked well enough or cannot be tolerated. It belongs to a class of drugs called biologics, which are made from living organisms and target specific parts of the immune system involved in inflammation.

How Entyvio Works

Unlike some other biologics that suppress the immune system more broadly, Entyvio is a gut-selective integrin receptor antagonist. This means it specifically targets alpha-4 beta-7 integrin, a protein found on the surface of certain white blood cells. By blocking this protein, Entyvio prevents these inflammatory cells from migrating from the bloodstream into the inflamed tissues of the gastrointestinal tract. This targeted action helps reduce inflammation in the gut while potentially minimizing systemic side effects.

Administration of Entyvio

Entyvio is administered as an intravenous (IV) infusion, typically in a clinic, hospital outpatient setting, or infusion center. The initial doses are given at specific intervals (e.g., at week 0, week 2, and week 6), followed by maintenance doses every 8 weeks. Each infusion usually takes about 30 minutes, plus observation time.

Understanding Medicare: A Brief Overview

Medicare is the federal health insurance program for people aged 65 or older, certain younger people with disabilities, and people with End-Stage Renal Disease (ESRD). It is divided into several parts, each covering different types of services.

• Medicare Part A (Hospital Insurance): Covers inpatient hospital stays, skilled nursing facility care, hospice care, and some home health care.
• Medicare Part B (Medical Insurance): Covers certain doctors' services, outpatient care, medical supplies, and preventive services. This is typically the most relevant part for Entyvio infusions.
• Medicare Part C (Medicare Advantage Plans): These are private insurance plans approved by Medicare that provide all Part A and Part B benefits. Many also include Part D (prescription drug) coverage and extra benefits like vision, hearing, or dental.
• Medicare Part D (Prescription Drug Coverage): Helps cover the cost of prescription drugs. This is crucial for self-administered medications or oral drugs for IBD.
• Medigap (Medicare Supplement Insurance): Private insurance plans that help pay for some of the out-of-pocket costs that Original Medicare (Parts A and B) doesn't cover, such as copayments, coinsurance, and deductibles.

Does Medicare Cover Entyvio?

The good news is that Medicare generally covers Entyvio, but the specific coverage depends on how and where the medication is administered, as well as the type of Medicare plan you have.

Entyvio Coverage Under Medicare Part B

Since Entyvio is an intravenously administered medication given by a healthcare professional in an outpatient setting (like a doctor's office, infusion center, or hospital outpatient department), it typically falls under Medicare Part B. Part B covers medically necessary outpatient services and supplies.

• Eligibility: For Part B to cover Entyvio, your doctor must deem the medication medically necessary for your condition (Crohn's disease or ulcerative colitis).
• Costs: With Original Medicare (Part B), after you meet your annual Part B deductible, you typically pay 20% of the Medicare-approved amount for the Entyvio infusion and the associated administration fees. Medicare pays the remaining 80%.
• Providers: You must receive the infusion from a Medicare-approved provider or facility.

Entyvio Coverage Under Medicare Part D

While Entyvio itself is an infused medication covered by Part B, individuals with IBD may also take other oral or self-administered medications as part of their treatment plan. Medicare Part D plans cover prescription drugs that you pick up at a pharmacy or receive through a mail-order service.

• What Part D Covers: If there were a self-injectable or oral form of vedolizumab (Entyvio is currently only IV), or if you take other oral medications for your IBD (e.g., corticosteroids, immunomodulators), Part D would cover those.
• Costs: Part D plans have varying formularies (lists of covered drugs), deductibles, copayments, and coinsurance amounts. You'll typically pay a copayment or coinsurance for each prescription, and you may enter a coverage gap (donut hole) where you pay a higher percentage of the drug cost.

Entyvio Coverage Under Medicare Part C (Medicare Advantage Plans)

Medicare Advantage plans, offered by private insurance companies, are an alternative to Original Medicare. These plans must cover everything Original Medicare (Parts A and B) covers, and many also include Part D prescription drug coverage (MAPD plans).

• Coverage: If you have a Medicare Advantage plan, it will cover your Entyvio infusions. However, the costs and rules may differ from Original Medicare.
• Network Restrictions: Medicare Advantage plans often have provider networks (HMOs, PPOs). You may need to receive your infusions from an in-network provider to get the best coverage. Out-of-network care may be more expensive or not covered at all.
• Prior Authorization: Many Medicare Advantage plans require prior authorization for high-cost medications like Entyvio. Your doctor will need to submit documentation to the plan demonstrating the medical necessity of the treatment.
• Costs: Your out-of-pocket costs (copayments, coinsurance, deductibles) will depend on your specific plan's benefits. Medicare Advantage plans have an annual out-of-pocket maximum, which can provide a cap on your spending.

Medigap (Medicare Supplement Insurance) and Entyvio

If you have Original Medicare (Parts A and B), a Medigap policy can help cover some of your out-of-pocket costs, including the 20% coinsurance for Part B services like Entyvio infusions. There are different Medigap plans (A, B, C, D, F, G, K, L, M, N), each offering varying levels of coverage for deductibles, copayments, and coinsurance.

• How it Helps: A Medigap plan can significantly reduce your financial burden by paying the 20% coinsurance for Entyvio infusions after Medicare Part B pays its 80%. Some plans also cover the Part B deductible.
• No Part D Coverage: It's important to remember that Medigap plans do not cover prescription drugs. If you have Original Medicare and a Medigap plan, you'll need a separate Part D plan for any covered prescription medications.

Out-of-Pocket Costs for Entyvio

Even with Medicare coverage, you will likely have out-of-pocket costs for Entyvio. These can include:

• Part B Deductible: You must pay the annual Part B deductible before Medicare starts paying its share.
• Part B Coinsurance: For Original Medicare, this is typically 20% of the Medicare-approved amount for the infusion and administration.
• Part D Deductible, Copayments, Coinsurance: If you're on other IBD medications covered by Part D, you'll face these costs.
• Medicare Advantage Plan Costs: These vary widely by plan but will include copayments or coinsurance for infusions and doctor visits.

The cost of Entyvio without insurance is extremely high, potentially thousands of dollars per infusion. Therefore, understanding and maximizing your Medicare benefits is essential.

Financial Assistance Programs for Entyvio

Given the high cost of Entyvio, several programs are available to help eligible patients manage their out-of-pocket expenses:

• Takeda Help at Hand Patient Support Program: Takeda, the manufacturer of Entyvio, offers a program that can help patients understand their insurance coverage, identify financial assistance options, and provide co-pay assistance for eligible commercially insured patients. While primarily for commercial insurance, they can often guide Medicare patients to other resources.
• Patient Assistance Programs (PAPs): Many pharmaceutical companies have PAPs that provide free or low-cost medications to eligible patients who are uninsured or underinsured and meet specific income criteria.
• Non-Profit Organizations: Foundations like the Crohn's & Colitis Foundation, Patient Access Network (PAN) Foundation, HealthWell Foundation, and The Assistance Fund offer financial assistance for medication costs, often specifically for Medicare beneficiaries. These programs typically have disease-specific funds and income requirements.
• Extra Help (Low-Income Subsidy): This is a Medicare program that helps people with limited income and resources pay for their Medicare Part D prescription drug costs, including premiums, deductibles, and coinsurance. While Entyvio is Part B, Extra Help is crucial for other IBD medications.

It is highly recommended to explore these options and contact the manufacturers' patient support programs or non-profit organizations for guidance.

Understanding Inflammatory Bowel Disease (IBD)

Entyvio is used to treat IBD, which includes Crohn's disease and ulcerative colitis. While this article focuses on coverage, it's important to understand the conditions Entyvio addresses.

Symptoms of IBD

Both Crohn's disease and ulcerative colitis share common symptoms, though their specific locations and patterns of inflammation differ:

• Persistent Diarrhea: Often bloody in ulcerative colitis.
• Abdominal Pain and Cramping: Can range from mild to severe.
• Rectal Bleeding: More common in ulcerative colitis.
• Weight Loss: Due to malabsorption and loss of appetite.
• Fatigue: A common symptom, often linked to anemia.
• Fever: Indicating inflammation or infection.
• Reduced Appetite: Leading to nutritional deficiencies.
• Anemia: Due to chronic blood loss or malabsorption.

Crohn's disease can affect any part of the digestive tract from mouth to anus, often in patches, and can involve all layers of the bowel wall. Ulcerative colitis affects only the colon and rectum, typically continuously, and primarily affects the innermost lining of the bowel.

Causes of IBD

The exact cause of IBD is not fully understood, but it is believed to involve a combination of factors:

• Genetics: IBD often runs in families, suggesting a genetic predisposition.
• Immune System Reaction: The immune system mistakenly attacks healthy cells in the digestive tract, leading to chronic inflammation.
• Environmental Factors: Diet, smoking, stress, and certain medications (like NSAIDs) may trigger or worsen symptoms in genetically predisposed individuals.
• Gut Microbiome: Imbalances in gut bacteria are also being investigated as a contributing factor.

Diagnosis of IBD

Diagnosing IBD typically involves a combination of tests:

• Medical History and Physical Exam: Your doctor will ask about your symptoms and family history.
• Blood Tests: To check for anemia, inflammation markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and nutritional deficiencies.
• Stool Tests: To rule out infections and check for blood or inflammatory markers (e.g., fecal calprotectin).
• Endoscopy and Colonoscopy: These procedures allow doctors to visualize the lining of the digestive tract and take biopsies for microscopic examination.
• Imaging Tests: CT scans, MRI, or capsule endoscopy may be used to look for inflammation, strictures, or fistulas in parts of the bowel not accessible by traditional endoscopy.

Treatment Options for IBD

Treatment for IBD aims to reduce inflammation, relieve symptoms, and achieve long-term remission. Options include:

• Anti-inflammatory Drugs: Aminosalicylates (5-ASAs) and corticosteroids.
• Immunomodulators: Azathioprine, mercaptopurine, methotrexate.
• Biologic Therapies: Medications like Entyvio, Humira, Remicade, Stelara, and Xeljanz, which target specific parts of the immune system.
• Small Molecule Drugs: Oral medications that target specific immune pathways, such as JAK inhibitors.
• Dietary Changes: While not a cure, certain dietary adjustments can help manage symptoms.
• Surgery: May be necessary for complications or when medical therapy is ineffective, especially in ulcerative colitis (colectomy) or severe Crohn's.

Entyvio is often considered when other treatments, such as corticosteroids or immunomodulators, have not been successful or cannot be tolerated.

When to See a Doctor

If you experience persistent changes in your bowel habits or any of the symptoms of IBD, it's crucial to see a doctor. Early diagnosis and treatment can help manage the condition and prevent complications. If you have already been diagnosed with IBD, you should contact your doctor if:

• Your symptoms worsen or change.
• You experience new or severe abdominal pain.
• You notice blood in your stool.
• You have unexplained weight loss or fatigue.
• You have a fever.
• You are experiencing side effects from your medication.

Regular follow-up with your gastroenterologist is essential for monitoring your condition and adjusting your treatment plan as needed.

Frequently Asked Questions (FAQs) About Entyvio and Medicare

Q1: Is Entyvio covered under Medicare Part A?

A: No, Entyvio infusions are generally not covered under Medicare Part A. Part A covers inpatient hospital stays. Since Entyvio is typically administered in an outpatient setting, it falls under Medicare Part B.

Q2: Do I need prior authorization for Entyvio with Medicare?

A: If you have Original Medicare (Parts A and B), prior authorization is less common but can occur for certain high-cost drugs or services. However, if you have a Medicare Advantage (Part C) plan, prior authorization for Entyvio is very common and almost always required. Your doctor's office will handle this process.

Q3: What if my Medicare Part D plan doesn't cover my other IBD medications?

A: If your Part D plan doesn't cover a specific IBD medication, you or your doctor can request an exception. If the exception is denied, you can appeal the decision. Alternatively, you may need to switch to a different Part D plan during the Annual Enrollment Period that covers your necessary medications.

Q4: Can I get financial help if I'm on Medicare and can't afford my Entyvio costs?

A: Yes, absolutely. Even with Medicare, out-of-pocket costs can be substantial. You should explore manufacturer patient assistance programs (like Takeda Help at Hand), independent charitable organizations (e.g., PAN Foundation, HealthWell Foundation), and Medicare's Extra Help program for Part D costs. Many organizations specialize in assisting Medicare beneficiaries with high drug costs.

Q5: Is there a generic version of Entyvio available?

A: As of the current time, there is no generic version of Entyvio (vedolizumab). Biologic medications like Entyvio are complex to manufacture, and biosimilar versions are typically developed rather than generics. While biosimilars for vedolizumab are under development, none are currently available on the market.

Q6: How can I find a Medicare Advantage plan that best covers Entyvio?

A: When choosing a Medicare Advantage plan, carefully review the plan's Evidence of Coverage (EOC) or contact the plan directly. Specifically, check the formulary for any associated oral medications for IBD and confirm their coverage for Part B infused medications like Entyvio. Pay close attention to network restrictions, prior authorization requirements, and out-of-pocket maximums. Consulting with a licensed Medicare broker or counselor from your State Health Insurance Assistance Program (SHIP) can be very helpful.

Conclusion

Entyvio is a vital treatment for many individuals living with moderate to severe Crohn's disease and ulcerative colitis. While its cost can be a significant concern, Medicare does provide coverage, primarily through Part B for the infusions. Understanding the nuances of Original Medicare (Parts A and B), Medicare Advantage plans (Part C), and the role of Medigap and Part D is crucial for managing your treatment expenses.

Don't hesitate to utilize available financial assistance programs from the manufacturer and non-profit organizations, as they can substantially reduce your out-of-pocket burden. Proactive engagement with your healthcare provider, insurance plan, and financial counselors will empower you to access the necessary care and maintain your quality of life while living with IBD.